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Abstract
Purpose After peptide receptor radionuclide therapy (PRRT),
renal toxicity may occur, particular in PRRTwith 90Y-labelled
somatostatin analogues. Risk factors have been identified for
increased probability of developing renal toxicity after PRRT,
including hypertension, diabetes and age. We investigated the
renal function over time, the incidence of nephrotoxicity and
associated risk factors in patients treated with PRRT with
[177Lu-DOTA0,Tyr3]-Octreotate (177Lu-Octreotate). Also,
radiation dose to the kidneys was evaluated and compared
with the accepted dose limits in external beam radiotherapy
and PRRTwith 90Y-radiolabelled somatostatin analogues.
Methods The annual decrease in creatinine clearance (CLR)
was determined in 209 Dutch patients and the incidence of
grade 3 or 4 renal toxicity (according to CTCAE v4.03) was
evaluated in 323 patients. Risk factors were analysed using a
nonlinear mixed effects regression model. Also, radiation
doses to the kidneys were calculated and their association with
high annual decrease in renal function were analysed.
Results Of the 323 patients, 3 (1 %) developed (subacute)
renal toxicity grade 2 (increase in serum creatinine >1.5–3.0
times baseline or upper limit of normal). No subacute grade 3
or 4 nephrotoxicity was observed. The estimated average
baseline CLR (±SD) was 108±5 ml/min and the estimated
average annual decrease in CLR (±SD) was 3.4±0.4%. None
of the risk factors (hypertension, diabetes, high cumulative
injected activity, radiation dose to the kidneys and CTCAE
grade) at baseline had a significant effect on renal function
over time. The mean absorbed kidney dose in 228 patients
was 20.1±4.9 Gy.
Conclusion Nephrotoxicity in patients treated with 177Lu-
octreotate was low. No (sub)acute grade 3 or 4 renal toxicity
occurred and none of the patients had an annual decrease in
renal function of >20 %. No risk factors for renal toxicity
could be identified. Our data support the idea that the radiation
dose threshold, adopted from external beam radiotherapy and
PRRT with 90Y-labelled somatostatin analogues, does not
seem valid for PRRTwith 177Lu-octreotate.
Keywords PRRT . 177Lu-Octreotate . Kidneys . Renal
function . Toxicity . Dosimetry . Nephrotoxicity
Introduction
Peptide receptor radionuclide therapy (PRRT) with
radiolabelled somatostatin analogues is increasingly being
used in patients with neuroendocrine tumours. Frequently
used somatostatin analogues are [90Y-DOTA0,Tyr3]-
octreotide (90Y-DOTATOC) and [177Lu-DOTA0,Tyr3]-
octreotate (177Lu-Octreotate). Although the side effects of this
therapy are mild, renal toxicity has been observed, particularly
in PRRT with 90Y-DOTATOC with an average annual
decrease in creatinine clearance (CLR) of 7 % in contrast
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to 3 % for 177Lu-Octreotate [1–4]. Also several risk factors
have been identified for developing renal toxicity after PRRT:
poor renal function, hypertension, and diabetes at baseline
[2, 5].
In the kidneys, radiolabelled somatostatin analogues are
reabsorbed in the renal proximal tubules [6]. A decrease in
renal uptake can be achieved by coinfusion of amino acids
during PRRT [7, 8]. Despite this renoprotection, there is
still a significant radiation dose to the kidneys. In the past,
the threshold dose for late-stage kidney radiation damage
was set at 23 Gy, which was the dose adopted from exter-
nal beam radiation therapy (EBRT) [9]. According to new
consensus guidelines, the limit for fractionated EBRT is set
at 18 Gy that results in late radiation damage to the kidneys
in 5 % of a treated population [10]. However, doses higher
than 23 Gy are safely given to patients receiving PRRT
with (mainly) 90Y-based somatostatin analogues [2, 11].
Here we present our dosimetric results and long-term
follow-up of a large number of patients treated with
177Lu-Octreotate. We also analysed the association
between known risk factors that have been indicated for
PRRT with 90Y-based somatostatin analogues [2, 5] and
change in renal function, including hypertension, diabetes,
cumulative injected activity, age, previous therapies and
poor renal function at baseline. In addition, radiation doses
to the kidneys were calculated and analysed.
Materials and methods
Patients
A total of 615 patients, who were treated from January 2000 to
December 2007 were studied. Inclusion criteria for the study
were: patients with somatostatin positive tumours and base-
line tumour uptake on [111In-DTPA0]Octreotide scintigraphy
(Octreoscan®; Mallinckrodt, Petten, The Netherlands) with
accumulation in the tumour at least as high as in normal liver
tissue; no prior treatment with PRRT; baseline serum
haemoglobin (Hb) ≥6 mmol/l; white blood cells ≥2 109/l;
platelets ≥75 109/l; Karnofsky performance status ≥50; serum
creatinine ≤150 μmol/l; and 24-h CLR ≥40 ml/min. Of the
615 patients, 323 Dutch patients were selected for this long-
term evaluation, because loss to follow-up is limited in these
patients.
This study was part of an ongoing prospective study in
patients with neuroendocrine tumours treated with 177Lu-
Octreotate at the Department of Nuclear Medicine,
Erasmus University Medical Center Rotterdam. The hos-
pital’s medical ethics committee approved the study. All
patients gave written informed consent for participation in
the study.
Treatment
[DOTA0,Tyr3]Octreotate was obtained from BioSynthema
(St. Louis, MO). 177LuCl3 was supplied by IDB-Holland
(Baarle-Nassau, The Netherlands) and 177Lu-Octreotate was
locally prepared [12].
Granisetron 3 mg or ondansetron 8 mg was injected intra-
venously 30 min before infusion of 177Lu-Octreotate. Infusion
of amino acids (2.5 % arginine and 2.5 % lysine, 1 l) was
started 30 min before administration of the radiopharmaceuti-
cal and lasted for 4 h. The radiopharmaceutical was
coadministered for 30 min using a second pump system. The
interval between treatments was 6–16 weeks. The intended
cumulative activity was 29.6 GBq (800 mCi). Median cumu-
lative activity was 29.6 GBq (range 7.4–29.6 GBq) and the
median number of therapy cycles was four (range one to
eight). However, the total administered activity was lowered
if the calculated kidney dose was higher than 23 Gy. Other
reasons for dose reduction or cessation of further therapy were
recurrent grade 3 or 4 haematological toxicity and persistently
low blood cell counts.
Toxicity, risk factor assessment and follow-up
Haematology, liver and renal function tests were performed
during the 6 weeks before the first therapy, 4 and 6 weeks after
each therapy, and at follow-up visits. Acute and long-term
renal toxicity assessment was done according to Common
Terminology Criteria for Adverse Events (CTCAE v4.0) [13].
Hypertension was defined as the use of antihypertensive
drugs (thiazide diuretics, beta blockers, ACE inhibitors, an-
giotensin II receptor antagonists and calcium channel
blockers). Diabetes mellitus was defined as an HbA1c of
≥6.0 % and/or the use of antidiabetic medication (insulin
and insulin sensitizers). CLR in millilitres per minute was
used as an estimate of glomerular filtration rate (GFR). Four
serum-based methods were used to determine baseline 24-h
urine CLR, and the results compared (see Supplementary
material). The Cockcroft-Gault (CG) formula had the highest
Spearman’s rank correlation coefficient. Therefore, changes in
renal function during follow-up were assessed in terms of
CLR determined using the CG formula:
CLR ml=minð Þ ¼ 140 age y½ ⋅weight kgð Þ
s creatinine μmol=Lð Þ ⋅ 0:85 i f female½ 
Statistical analysis
SPSS (SPSS 19; IBM, Armonk, NY) and R (R 3.2.2; R
Foundation for Statistical Computing, Vienna, Austria) soft-
ware was used for statistical analysis. The Shapiro-Wilk test
was used to assess the normality of the response. The primary
Eur J Nucl Med Mol Imaging
outcome was CLR predicted by a nonlinear mixed ef-
fects regression model with independent factors (hyper-
tension, diabetes, cumulative injected activity, radiation
dose to the kidneys, age and CTCAE at baseline).
Various functional model forms (linear, nonlinear, poly-
nomial and spline) were fitted to the CLR data (see
Supplementary material). The nonlinear model with the
monoexponential function performed best
where bb0 is the estimated average CLR at time 0 when all other
covariates are zero, and bb1 is the estimated average change in
CLR in percent/time. Time is expressed in weeks and factor1
and factor2 are constants, given specific values of the covariates
included in the mixed model. The combined term cðb0 factor1Þ
represents the estimated average CLR at time=0 for a specific
covariate pattern, whereas cðb1 factor2Þ is the estimated average
percentage decrease/increase in CLR per week. Random effects
were included on both the intercept and slope parameters, and a
diagonal covariance matrix was assumed.
Dosimetry
Uptake of radioactivity in the kidneys was determined by
planar imaging at 1, 3–4 and 7 days after administration of
177Lu-Octreotate. Extensive information regarding the dosi-
metric method is provide in an earlier paper [12]. Dosimetry
values were computed with S-factors for 177Lu derived from
the Radiation Dose Assessment Resource (RADAR) website
[14, 15]. The general scheme for calculating radiation dosim-
etry with radionuclides has been defined by theMIRD scheme
dosimetry formula [16]:








~AS ⋅S rt←rSð Þ
¼ ≫Dkidneys≈~Akidneys⋅S kidneys←kidneysð Þ
The dose to the target organ (Dkidneys) is calculated as the
product of the number of decays in a source organ (Ãs) and the
S-value, which expresses the dose rate per radioactivity for a
source (rs) to target (rt) combination. With moderately weak
β-particle-emitting radionuclides such as 177Lu, only the self-
dose needs to be considered (rs = rt). The radioactivity uptake
and clearance kinetics of 177Lu-Octreotate As(t) in the kidneys
is needed for calculation of the radiation dose to the kidneys,
together with the S-value for the kidney self-dose. The 177Lu
S-values were taken from the RADAR website [15]: for adult
male kidneys (with a mass of 299 g) the S-value is 0.289mGy/
MBq.h and for a adult female kidneys (with a mass of 275 g)
the S-value is 0.314 mGy/MBq.h. In a subgroup of patients,
the kidney volume was determined based on baseline CT im-
ages, since complete kidney imaging was not always avail-
able. A correction factor and adjusted dose were calculated in
these patients, using OsiriX 5.9 (Pixmeo Sàrl, Bernex,
Switzerland). A polygonal region of interest was
(semi)automatically drawn on each CT slice and the slices
were summed for calculation of the total kidney volume.
Results
In 554 patients the inclusion criteria were met. In-depth eval-
uation was done in 322 Dutch patients (excluding one patient
with no baseline CLR). Patient characteristics are summarized
in Table 1. A Spearman’s correlation coefficient of 0.76 was
found between baseline 24-h urine and serum-based CLR
(Fig. 1).
Kidney toxicity
Of the 323 patients, 14 (4 %) had a (sub)acute toxicity grade 1
(creatinine increase >26.5 µmol/l). Three patients (1 %) de-
veloped (subacute) toxicity grade 2 (creatinine increase >1.5–
3.0×baseline or upper limit of normal). These were judged
not related to therapy: one patient had received prolonged
antibiotics due to an infection and developed temporary renal
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insufficiency, one patient was dehydrated because of diar-
rhoea, and one patient showed progression of disease with
hypoalbuminaemia and forward heart failure resulting in
death 2 weeks after the first treatment. No grade 3 or 4
(sub)acute nephrotoxicity was observed.
Follow-up data for 1, 2 and 3 years after the last therapy were
available in 209, 155 and 98 patients, respectively. Grade 3
kidney toxicity was observed in 5 out of the 323 patients during
this follow-up. Toxicity was not related to PRRT since all five
patients had a baseline CLR of <60 ml/min (i.e. grade 2),
making them more prone to more severe renal function impair-
ment. However, the annual decrease in CLR was <12 %. The
distribution of CLR at baseline and during follow-up (1, 2 and 3
years after inclusion) is shown in Fig. 2. Reasons for loss to
follow-up after 1, 2 and 3 years are summarized in Table 2.
One patient was lost to follow-up after 2 years, due to kidney
failure resulting in dialysis based on preexisting kidney disease.
Long-term change in renal function
Follow-up of more than 1 year was available in 209 of the 323
patients. One patient with an incomplete set of risk factors was
excluded; thus the analysis included 208 patients. The estimat-
ed average annual decrease in CLR (±SD) was 3.4±0.4 %,
and the estimated average baseline CLR ( bb0 ) was 108±5 ml/
min (Fig. 3). The time course of CLR and the fitted nonlinear
model in an example patient are shown in Fig. 4. In 203 out of
208 patients, the annual decrease in renal function was <10 %.
Five patients had an annual decrease in CLR of ≥10 %, and
two patients had an annual decrease of ≥15 % (Fig. 5). In 29
(14 %) of 208 patients, a positive annual change in CLR
(improvement in renal function) was observed. No patient
showed an annual decrease in renal function of ≥20 %.
Table 1 Baseline characteristics of 323 Dutch patients
Characteristic no.
Gender
Male 158 (49 %)
Female 165 (51 %)
Age (years)
≥70 63 (20 %)
<70 260 (80 %)
Karnofsky performance status
≤70 46 (14 %)
>70 277 (86 %)
Diabetes
Yes 104 (32 %)
No 219 (68 %)
Hypertension
Yes 77 (24 %)
No 246 (76 %)
Solitary kidney
Yes 10 (3 %)
No 313 (97 %)
Previous therapy
Radiotherapy (external)
Yes 32 (10 %)
No 291 (90 %)
Chemotherapy 39 (12 %)
Cisplatin 5 (13 %)
Other 34 (87 %)
Tumour type
Neuroendocrine tumour 281 (87 %)
Other 42 (13 %)
Dosimetry
Dosimetric data available 228 (71 %)
Limit 23 Gy to the kidneys
Yes 55 (24 %)
No 173 (76 %)
Volume of kidneys available
Yes 119 (52 %)
No 109 (48 %)
Cumulative activity (GBq)
Up to 22.2 106 (33 %)
Up to 29.6 217 (66 %)
Kidneys
Baseline creatinine clearance
<60 ml/min/1.73 m2 37 (11 %)
≥60 ml/min/1.73 m2 286 (89 %)
Baseline Cockcroft-Gault creatinine clearance (ml/
min), median (range)
95 (34 – 245)
Follow-up (months), median (range) 25 (0 – 142)
Fig. 1 Baseline 24-h urine creatinine clearance (CLR) versus serum-
based CLR according to the Cockcroft-Gault formula in 281 of 323 pa-
tients. The solid line is the linear regression line with a slope of 1 with
95 % confidence intervals (dotted lines)
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Risk factor assessment
Age and baseline CTCAE had significant effects on the base-
line CLR (both p<0.0001). With all other factors held con-
stant, the estimated average baseline CLR showed a signifi-
cant decrease in patients older than 70 years or with baseline
CTCAE grade 2. None of the risk factors considered for in-
clusion in the model (hypertension, diabetes, age >70 years,
cumulative injected activity >22.2 GBq, high radiation dose to
the kidneys and CTCAE grade at baseline) had a significant
effect on the estimated rate of change in CLR over time, and
were thus not included in the final model.
Dosimetry
Dosimetric data for kidney dose calculations was available in
407 of the 554 on-protocol patients. In 147 patients no radia-
tion dose to the kidneys could be calculated due to incomplete
dosimetric data and/or over-projection of tumour nodules on
planar images of the kidney region of interest. Clearance of
radioactivity from the kidneys proceeded with a median effec-
tive half-life of 58 h (range: 27–135 h) in 407 patients. The
mean radiation dose to the kidneys was 19.3 ± 5.0 Gy
(Fig. 6a). The mean kidney absorbed dose for a hypothetical
dose distribution of 4×7.4 GBq of 177Lu-Octreotate was 19.8
±5.8 Gy (Fig. 6b). The mean calculated radiation dose to the
kidneys in 228 of the 323 Dutch patients in whom it could be
calculated was 20.1±4.9 Gy (Fig. 6c), and 11 (5 %) of these
228 patients had a calculated kidney absorbed dose of more
than 28 Gy. The total administered injected activity was re-
duced in 55 of the 228 patients because the calculated kidney
dose was more than 23 Gy. The average measured kidney vol-
ume (with corresponding mass) in 119 (49 %) of the 228 pa-
tients in whom it could be measured was a factor of 0.95 (range
0.49–1.71) less than the fixed phantom-based kidney mass.
Discussion
After PRRT with 177Lu-Octreotate, the average annual de-
crease in CLR was 3 % and no patient showed a decrease of
more than 20 %, which is in line with the results of other
studies with 177Lu-Octreotate [2, 5, 17, 18]. Of the patients
treated with 177Lu-Octreotate, 14 % showed an annual im-
provement in CLR. Tumour response and improvement in
clinical condition could explain the increase in CLR in these
patients, since a rapid weight gain with stable serum creatinine
values results in a higher CLR. Therefore, we suspect that the
Table 2 Cumulative numbers of
323 Dutch patients lost to follow-
up 1, 2 and 3 years after the last
PRRT
Reason lost to follow-up After 1 year After 2 years After 3 years
Progressive disease 43 47 56
Death 8 9 12
Follow-up elsewhere (patient request) 18 23 32
Complications (e.g. bleeding, infection, ileus, dyspnoea) 11 13 19
Bone marrow suppression 4 7 9
Liver failure 2 2 2
Other therapy 23 28 40
Octreoscan-negative lesions during follow-up 2 2 3
Retreatment with 177Lu-DOTATATE 3 37 51
Kidney failure (see text) 0 0 1
Total number of patients 114 168 225
Fig. 2 Distribution of creatinine clearance in 323 patients according to
Common Terminology Criteria for Adverse Events (CTCAE) classifica-
tion at baseline, and at 1, 2 and 3 years after inclusion. Number (N) of
patients with serum creatinine available / total number of patients in
follow-up. No CTCAE grade 4 was observed
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improvement in CLR did not reflect a true improvement in
renal function.
In practice, an annual decrease of 3 % means a CLR of 91
ml/min after 3 years in a patient with normal renal function at
baseline (Table 3). Five of our patients had an annual decrease
in renal function of more than 10%, translating to a CLR after
3 years of 74 ml/min in an individual with normal renal func-
tion at the start. Since the overall survival following PRRT
with 177Lu-octreotate is 3 to 4 years [19], it is unlikely that
the kidneys are the long-term limiting factor. A decrease in
renal function to CTCAEgrade 2 or higher occurs after 7 years
in a patient with normal renal function at the start and an
annual decrease of 10 % (Table 3). In our study, only 1 % of
the patients developed therapy-unrelated severe (grade 3) re-
nal toxicity after 1 year. Furthermore, the CTCAE distribution
of CLR over time did not change, confirming the low neph-
rotoxicity of PRRTwith 177Lu-Octreotate.
Several risk factors for kidney toxicity after PRRT with
mainly 90Y-labelled somatostatin analogues have been
identified, including age (>60 years), diabetes, hypertension,
previous chemotherapy and poor baseline renal function [1, 2,
4]. In a recent study [5], renal function was analysed in 807
patients treated with 177Lu-Octreotate and/or 90Y-Octreotide.
Hypertension was identified as a main risk factor for
(persistent) nephrotoxicity. However, nephrotoxicity was de-
fined as a categorical outcome according to CTCAE,
neglecting the change in renal function over time. This can
lead to a simplified representation of kidney toxicity after
PRRT and false identification of risk factors. Valkema et al.
analysed renal function in 37 patients treated with 177Lu-
Octreotate by taking the subject-specific annual decrease in
CLR extracted from fitted monoexponential curves [1].
Hypertension was also found to be a possible factor contrib-
uting to the rate of decrease in CLR after PRRT. Although the
authors did take into account the change in renal function over
time, they were unable to determine the impact of covariates
on the change over time but only on summary measurements
obtained from individually fitted curves.
Given the repeated measurement structure of the data and
the need to assess the effect of risk factors on both baseline
CLR and change in CLR over time, a more advanced ap-
proach is required. We therefore used a mixed effects regres-
sion model. Mixed effects models are the standard modelling
framework for the analysis of longitudinal data. These models
explicitly account for differences in correlation structure of the
data within/between patients and deal well with unbalanced
data (varying times of measurement in each subject and un-
equal numbers of follow-up measurements among subjects).
In our present analysis, age >70 years and baseline CTCAE
grade influenced the nonlinear model. However, the two risk
factors only changed the estimated average baseline CLR
component in our model, meaning that patients older than
70 years and/or patients with baseline CTCAE grade 2 had a
lower estimated average CLR at baseline. None of the
Fig. 5 Distribution of the change in creatinine clearance per year in 208
patients with long-term follow-up. Note the log scale on the y-axis.
Coloured bars represent annual loss of renal function < 10% (blue), 10-
15% (yellow) and >15% (orange)
Fig. 4 Time-course of creatinine clearance (CLR) and fitted
monoexponential decay (solid line) in a 71-year-old patient with a neu-
roendocrine tumour, hypertension and diabetes, who received
4 × 7.4 GBq 177Lu-Octreotate. The estimated decrease in CLR is
11.4 % per year
Fig. 3 Nonlinear model of creatinine clearance (CLR) over time based
on 208 patients. Solid line is the exponential function with 95 % confi-
dence interval (dashed lines). The estimated average baseline CLR (±SD)
is 108 ± 5 ml/min and the estimated average annual change in CLR
(± SD) is 3.4 ± 0.4 %
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evaluated risk factors modified the percentage CLR change
component significantly, implying that the percentage change
in CLR over time in patients with risk factors was not different
from that in patients without risk factors.
An explanation for our results could be that the frequency
of nephrotoxicity after PRRTwith 177Lu-Octreotate is low and
a higher number of patients would be required to show statis-
tical significance of the risk factors. For the same reason, we
were not able to compare patients with/without a solitary kid-
ney and with/without alkylating chemotherapy (e.g. cisplatin).
The relatively low numbers of patients resulted in low statis-
tical power for testing these risk factors.
GFRmeasurement with inulin is the gold standard for mea-
suring renal function, but practical implementation is difficult
[20]. Other radionuclide-based filtration markers such as
99mTc-MAG3 (mercaptoacetyltriglycine) are used for accurate
assessment of renal function in clinical practice [21].
However, these methods are expensive and time-consuming
in the follow-up of large patient groups. We used CLR as an
indirect marker for estimating GFR since serum creatinine is
widely available. Also most of our patients had normal baseline
renal function, making CLR a reasonable estimator for GFR.
However, different formulas for calculation of renal function
are available: the (body surface area-corrected) CG formula
and the (abbreviated) modification of diet in renal disease
(MDRD) equations. The CG formula estimates CLR [22],
whereas theMDRD equations estimate GFR [23]. All formulas
have different performance in various subgroups of patients
depending on age, sex, weight and range of renal function
[24]. Therefore, we calculated Spearman’s rank correlation co-
efficients for different equations versus 24-h urine CLR in our
patient group. The CG formula had the best correlation (Fig. 1).
Our results are in line with those of other studies indicating that
CG is more precise than MDRD [24], meaning that individual
changes in renal function over time are more reliable.
Radiation toxicity dose effect models used in PRRT are pre-
dominantly based on the experience and knowledge obtained
from EBRT. In the past, the threshold dose for late-stage kidney
radiation damage for EBRTwas set at 23 Gy [9]. However, the
tolerable dose in current guidelines for radiotherapy-associated
kidney injury are lower at 18 Gy [10]. Kidney radiation doses
of 18 Gy given in a fractionation scheme of 2 Gy per fraction
are considered to result in a 5 % probability of developing
radiation nephropathy during the 5 years after EBRT.
For PRRT with 90Y-DOTATOC, a correlation was found
between the kidney absorbed dose and chronic kidney toxic-
ity. The dose at which 5 % of patients will show kidney tox-
icity has been estimated at 24 Gy for 90Y-DOTATOC [11].
Another study has confirmed this dose limit in 22 of 50 pa-
tients treated with 90Y-DOTANOC [25]. The absorbed dose
limit after 90Y irradiation and that for fractionated EBRT can
be compared using the concept of the biologically effective
dose (BED). BED is a measure of the true biological dose
delivered at a particular dose rate and fractionation pattern,
tissue-specific for a relevant biological end-point (in this case
late-stage renal disease). It takes the protracted nature of the
absorbed dose delivery by radionuclides into account by
adjusting the kidney’s radiation sensitivity for the repair of
sublethal radiation damage during the absorbed dose build-
up according to the linear quadratic (LQ) model. The BED
concept is thought to explain the 6-Gy higher dose limit than
Fig. 6 Distribution in 1-Gy increments of the radiation dose to the kidneys
for 407 patients and in 228 patients with quantifiable kidney uptake: a actual
distribution in 407 patients; b hypothetical distribution for 4×7.4 GBq of
177Lu-Octreotate; c actual distribution in 228 Dutch patients. Gaussian fits
(dashed lines) are overlain on the histograms. The green arrow indicates the
kidney threshold dose (18 Gy) according to current EBRT guidelines [10].
The orange arrow (24 Gy) and red arrow (28 Gy) correspond to the PRRT
dose limits for kidney damage according to Wessels et al. [11] and Bodei et
al. [2], respectively, for therapies given in four cycles
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the 18 Gy accepted for EBRT [10]. Bodei et al. proposed a
BED limit of 40 Gy to the kidneys in patients without risk
factors and a BED of 28 Gy in patients with risk factors,
corresponding to absorbed doses of 28 and 24 Gy, respective-
ly (both given in four fractions) [2]. A summary of previously
reported kidney dosimetry findings in studies using 177Lu-
Octreotate is provided in Table 4.
In this study, we did not find a significant difference in the
effect of kidney dose on renal function. Most patients received
a kidney dose of less than 28Gy (Fig. 6c). However, in a small
number of patients the kidney dose exceeded this limit. In our
long-term follow-up group, 11 patients received a kidney dose
that exceeded 28Gy. None of these patients developed grade 3
or 4 nephrotoxicity and/or had an annual decrease in CLR of
more than 10%. Therefore, the 28 Gy dose limit seems to be a
conservative value for PRRT with 177Lu-Octreotate. Another
argument for a higher dose limit is that 177Lu has shorter range
β-particles than 90Y. This results in less damage to nearby
nontarget tissue and (theoretically) in fewer cases of nephro-
toxicity at a fixed kidney dose [26–28].
In PRRT studies, the LQ model concept of BED was first
introducedwith dosimetric data from 18 patients who received
90Y-DOTATOC [29]. A stronger correlation was observed
with the decrease in CLR when applying this model, com-
pared with using absorbed renal dose alone. Also, a compar-
ison between the relatively high dose-rate of EBRT and low
dose-rate irradiation of radionuclide therapy is possible using
BED. The LQmodel can be used to analyse the effects of dose
rate, number of therapy cycles in EBRT/PRRTand the type of
radionuclide in PRRT. The LQ model-based BED for PRRT
has been adopted by the Committee on Medical Internal
Radiation Dose (MIRD) for late kidney damage [11]. In
PRRT little scientific evidence is available for the choice of
α/β ratio and repair T1/2, which represents the damage and
repair half-life in the BED model, however the two variables
have an important effect on the dosimetric outcome [30, 31].
Also, since no severe renal toxicity was observed in the
present study with an intended dose scheme of
4 × 7.4 GBq, reporting the BED did not seem appropri-
ate. Moreover, in the present study the factor relating
Table 4 Reported data on kidney dosimetry for PRRTwith 177Lu-Octreotate




Amino acids Dose to kidneys
Per activity
administered (Gy/GBq)
For 4 × 7.4 GBq (Gy)
[12] Planar 5 1.85 Lys/Arg 0.9 ± 0.2 26.6 ± 5.3
[2] Planar 5 3.7 – 5.18 Not reported 0.9 ± 0.5 26.6 ± 13.3
[32] Planar 69 3 – 7 Lys/Arg 0.9 ± 0.3 26.6 ± 8.0
[33] SPECT/CT 24 7.4 Vamin 14 0.7 ± 0.3 20.7 ± 6.2
[34] SPECT/CT 16 7.4 Vamin 14 0.9 ± 0.3 26.6 ± 8.0
[35] Planar 26 8 Not reported 0.9 ± 0.4 26.6 ± 10.6
[36] SPECT/CT 33 7.8 Synthamin 0.3 (0.1 – 0.5) 9.2 (4.1 – 13.6)
[18] Planar 12 5.18 – 7.4 Lys/Arg 0.8 ± 0.4 23.7 ± 9.5
[37] SPECT/CT 200 7.4 Vamin 14 1.2 ± 0.6 36.3 ± 16.0
[28] Planar 51 3.5 – 8.2 Lys/Arg 0.8 ± 0.4 23.7 ± 9.5
This study Planar 407 7.4 Lys/Arg 0.7 ± 0.2 19.8 ± 5.8
Values are means ± SD, or median (range)
Lys/Arg Lysine 2.5 % and arginine 2.5 %, Lys Lysine 2.5 %
Table 3 Creatinine clearance in
hypothetical patients with a
baseline renal function of 100 ml/
min and annual decreases of 3 %,
10 % and 20 %
Year Creatinine clearance (ml/min)
3 % annual decrease 10 % annual decrease 20 % annual decrease
0 100 100 100
3 91 74 55a
5 86 61 37a
7 81 50a 25a
a Creatinine clearance of CTCAE grade 2 or higher
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absorbed dose and BED was low: median 1.09 (range
1.02 – 1.21).
Our results demonstrate that the kidneys are not the dose-
limiting organ in patients treated with 177Lu-Octreotate.
Therefore, in clinical practice, kidney dosimetry does not cur-
rently have a prominent place in PRRT with 4 × 7.4 GBq
177Lu-Octreotate. However, (serum-based) assessment of re-
nal function during and after PRRT is mandatory since renal
toxicity unrelated to PRRT could occur. Also measurement of
renal function at baseline is required since low GFR is a risk
factor for development of (sub)acute haematotoxicity after
PRRT.
Conclusion
The number of patients with nephrotoxicity after PRRT with
177Lu-Octreotate is low. No patient showed (sub)acute grade 3
or 4 nephrotoxicity or an annual decrease in renal function of
>20 %. No risk factors (e.g. hypertension, diabetes) leading to
an additional annual decrease in renal function could be iden-
tified. Our study showed that the maximum radiation dose to
the kidney adopted from EBRT and PRRT with 90Y-labelled
analogues does not seem to apply to PRRT with 177Lu-
Octreotate.
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